Read More Pharma Industry News MBX Biosciences stock surges 160% after Canvuparatide Phase 2 success in hypoparathyroidism MBX Biosciences (NASDAQ: MBX) jumps 160% after Canvuparatide Phase 2 success in hypoparathyroidism; see trial data, stock reaction, and Phase 3 outlook. byPallavi MadhirajuSeptember 22, 2025